Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: Influence of protein binding

Anti-Cancer Drugs

Volumn 16, Issue 9, 2005, Pages 1009-1016

  Royer, Bernard ^a   Guardiola, Emmanuel ^a   Polycarpe, Emmanuel ^a   Hoizey, Guillaume ^b   Delroeux, Delphine ^a   Combe, Marielle ^a   Chaigneau, Loïc ^a   Samain, Emmanuel ^a   Chauffert, Bruno ^c   Heyd, Bruno ^a   Kantelip, Jean Pierre ^a   Pivot, Xavier ^a  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b HÔPITAL MAISON BLANCHE   (France)

^c INSERM   (France)

Author keywords

Cisplatin; i.p. infusion; Ovarian cancer; Pharmacokinetics

Indexed keywords

CARBOPLATIN; CISPLATIN; PACLITAXEL; PLASMA PROTEIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DIFFUSION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PERITONEAL FLUID LEVEL; DRUG PROTEIN BINDING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; OVARY CANCER; PEROPERATIVE CARE; PRIORITY JOURNAL; PROTEIN ANALYSIS;

AGED; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; ASCITIC FLUID; BLOOD PROTEINS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFUSIONS, PARENTERAL; INTRAOPERATIVE PERIOD; MIDDLE AGED; OVARIAN NEOPLASMS; PROTEIN BINDING;

EID: 26244467122     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000176505.94175.d4     Document Type: Article

References (33)

1. Almadrones LA. Treatment advances in ovarian cancer. Cancer Nurs 2003; 26:163-203.
2. Ozols RF. Update on the management of ovarian cancer. Cancer J 2002; 8:22-30.
3. Carmignani CP, Sugarbaker PH. Comprehensive approach to advanced primary and recurrent ovarian cancer: a personal experience. Expert Rev Anticancer Ther 2004; 4:477-487.
4. Stuart GC. First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer. Gynecol Oncol 2003; 90:8-15.
5. Reichman B, Markman M, Hakes T, Hoskins W, Rubin S, Jones W, et al. Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma. J Clin Oncol 1989; 7:1327-1332.
6. Howell SB, Kirmani S, Lucas WE, Zimm S, Goel R, Kim S, et al. A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer. J Clin Oncol 1990; 8:137-145.
7. Markman M, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, et al. Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinoma. J Clin Oncol 1991; 9:204-210.
8. Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19:1001-1007.
9. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335:1950-1955.
10. Topuz E, Eralp Y, Saglam S, Saip P, Aydiner A, Berkman S, et al. Efficacy of intraperitoneal cisplatin as consolidation therapy in patients with pathologic complete remission following front-line therapy for epithelial ovarian cancer. Consolidative intraperitoneal cisplatin in ovarian cancer. Gynecol Oncol 2004; 92:147-151.
11. Look M, Chang D, Sugarbaker PH. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer 2004; 14: 35-41.
12. Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol 2003; 4:277-283.
13. Rossi CR, Mocellin S, Pilati P, Foletto M, Quintieri L, Palatini P, et al. Pharmacokinetics of intraperitoneal cisplatin and doxorubicin. Surg Oncol Clin N Am 2003; 12:781-794.
14. Chauffert B, Favoulet P, Polycarpe E, Duvillard C, Beltramo JL, Bichat F, et al. Rationale supporting the use of vasoconstrictors for intraperitoneal chemotherapy with platinum derivatives. Surg Oncol Clin N Am 2003; 12:835-848.
15. Ahmad SA, Kim J, Sussman JJ, Soldano DA, Pennington LJ, James LE, et al. Reduced morbidity following cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion. Ann Surg Oncol 2004; 11:387-392.
16. Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW, et al. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res 1983; 43: 5379-5389.
17. Kern W, Braess J, Kotschofsky M, Samel S, Becker H, Hiddemann W, et al. Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: analysis of pharmacokinetics and of nephrotoxicity. Anticancer Res 2002; 22: 3099-3102.
18. Urien S, Lokiec F. Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. Br J Clin Pharmacol 2004; 57:756-763.
19. O'Dwyer PJ, Stevenson JP, Johnson SW. Clinical pharmacokinetics and administration of established platinum drugs. Drugs 2000; 59: 19-27.
20. Chatelut E, de Forni M, Canal P, Chevreau C, Roche H, Plusquellec Y, et al. Teniposide and cisplatin given by intraperitoneal administration: preclinical and phase I/pharmacokinetic studies. Ann Oncol 1991; 2:217-221.
21. Panteix G, Beaujard A, Garbit F, Chaduiron-Faye C, Guillaumont M, Gilly F, et al. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy. Anticancer Res 2002; 22:1329-1336.
22. Pivot X, Marghali N, Etienne MC, Bensadoun RJ, Thyss A, Otto J, et al. A multivariate analysis for predicting cisplatin-induced delayed emesis. Oncol Rep 2000; 7:515-519.
23. Pivot X, Chamorey E, Guardiola E, Magne N, Thyss A, Otto J, et al. Phase I and pharmacokinetic study of the association of capecitabine-cisplatin in head and neck cancer patients. Ann Oncol 2003; 14:1578-1586.
24. Urien S, Brain E, Bugat R, Pivot X, Lochon I, Van ML, et al. Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients. Cancer Chemother Pharmacol 2005; 55:55-60.
25. Tegeder I, Brautigam L, Seegel M, Al-Dam A, Turowski B, Geisslinger G, et al. Cisplatin tumor concentrations after intra-arterial cisplatin infusion or embolization in patients with oral cancer. Clin Pharmacol Ther 2003; 73:417-426.
26. Tsujitani S, Fukuda K, Saito H, Kondo A, Ikeguchi M, Maeta M, et al. The administration of hypotonic intraperitoneal cisplatin during operation as a treatment for the peritoneal dissemination of gastric cancer. Surgery 2002; 131:98-104.
27. Pivot X, Guardiola E, Etienne M, Thyss A, Foa C, Otto J, et al. An analysis of potential factors allowing an individual prediction of cisplatin-induced anaemia. Eur J Cancer 2000; 36:852-857.
28. Dumas M, de Gislain C, d'Athis P, Chadoint-Noudeau V, Escousse A, Guerrin J, et al. Influence of hydration on ultrafilterable platinum kinetics and kidney function in patients treated with cis-diamminedichloroplatinum(II). Cancer Chemother Pharmacol 1990; 26:278-282.
29. Kern W, Braess J, Kaufmann CC, Wilde S, Schleyer E, Hiddemann W. Microalbuminuria during cisplatin therapy: relation with pharmacokinetics and implications for nephroprotection. Anticancer Res 2000; 20: 3679-3688.
30. van de Vaart PJ, van der Vange N, Zoetmulder FA, van Goethem AR, van Tellingen O, ten Bokkel Huinink WW, et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer 1998; 34:148-154.
31. Fournier C, Vennin P, Hecquet B. Correlation between free platinum AUC and total platinum measurement 24 h after i.v. bolus injection of cisplatin in humans. Cancer Chemother Pharmacol 1988; 21:75-77.
32. de Jongh FE, Verweij J, Loos WJ, de Wit R, de Jonge MJ, Planting AS, et al. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 2001; 19:3733-3739.
33. Cho HK, Lush RM, Bartlett DL, Alexander HR, Wu PC, Libutti SK, et al. Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis. J Clin Pharmacol 1999; 39:394-401.